Touch Medical Media coverage of data presented at EADV 2023:
Brentuximab vedotin, an antibody–drug conjugate, was approved for the treatment of cutaneous T-cell lymphoma (CTCL) in Europe in 2017. In this touchDERMATOLOGY interview, we spoke with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) to discuss the rationale and findings from his observational open-label study of brentuximab vedotin for CTCLs, assessing the real-world efficacy and safety of the ADC in Poland.
The abstract ‘Real-world outcomes of brentuximab vedotin treatment in patients with CD30-expressing cutaneous T-cell lymphoma: 24‑week interim analysis of a prospective, multicenter, observational study in Poland.’ (Abstract N°: 6587) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.
Questions
- What challenges are associated with treating advanced cutaneous T-cell lymphomas (CTCLs)? (0:21)
- Could you give us a brief overview of the findings from the phase 3 ALCANZA trial? (0:54)
- What were the aims and design of the observational open-label study you presented at EADV? (1:55)
- What were the real-world efficacy and safety findings from your study? (2:37)
- How will these insights optimise the use of brentuximab vedotin for CTCLs? (3:19)
Disclosures: Adam Reich discloses receiving grant/research support from Abbvie, Anaptys, BMS, Dice, Eli Lilly, Galderma, Incyte, Jannsen, Medac, Novartis, Pfizer, Regeneron, Trevi Therapeutics, and UCB; serving on advisory boards for Abbvie, Galderma, Leo Pharma, Sanofi, Novartis, and Eli Lilly.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.
Filmed in coverage of the EADV Annual Meeting.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
Click here for more content on dermato-oncology & for further EADV 2023 highlights visit here.
